Exelixis Enters Exclusive Licensing Agreement With StemSynergy For CK1a Activator Program, Will Pay StemSynergy $3M Upfront And Up To $3.5M In R&D Funding, In Addition To Variety Of Milestone Payments
Hal Lindon